Posted by Michael Wonder on 26 Mar 2024
Astellas' Vyloy (zolbetuximab) approved in Japan for treatment of gastric cancer
26 March 2024 - MHLW approval makes Vyloy the first and only CLDN18.2-targeted therapy approved in the world.
Astellas today announced that on 26 March 2024, Japan's Ministry of Health, Labour and Welfare approved Vyloy (zolbetuximab), an anti-claudin 18.2 monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
